A review of public procurement data from 2021 to mid‑2026 shows that Công ty CP Đầu tư Y tế Việt Mỹ (Viet My) has become the predominant supplier of high‑cost radiotherapy and nuclear medicine equipment in Vietnam.
Quảng Ninh
In Quảng Ninh, the firm appeared in 13 tender dossiers linked to Bệnh viện Bãi Cháy, winning 12 contracts worth more than VND 217 billion, including a near‑VND 200 billion Cyclotron project and multiple maintenance packages for Elekta linear accelerators. All but one of these bids were uncontested, with Viet My often the sole participant and the awarded price matching the approved budget.
Central Highlands
In the Central Highlands, Viet My secured a VND 127 billion contract for a linear accelerator at the upgraded Cancer Center of Đắk Lắk Provincial Hospital. The tender, opened on 2 February 2024, attracted only Viet My; the company’s bid matched the estimated price, and the expert panel confirmed its technical and financial qualifications after a series of document clarifications.
Ho Chi Minh City
Further illustrating its market dominance, Viet My won 24 of 27 tenders at Ho Chi Minh City’s Bệnh viện Chợ Rẫy, with a cumulative value exceeding VND 600 billion. Highlights include:
- Three VND 17‑21 billion maintenance contracts for Elekta radiotherapy systems (November 2024)
- A VND 199.8 billion Cyclotron supply (June 2025)
- A VND 22.14 billion 36‑month service contract for the Gamma Knife system (July 2025)
Most contracts were awarded without competition, and the firm’s prices either matched or slightly undercut the original estimates.
Collectively, these procurements demonstrate Viet My’s near‑monopoly in supplying sophisticated oncology equipment to Vietnam’s public hospitals, raising questions about competitive bidding practices while underscoring the company’s technical capacity and long‑term service commitments.